Healthcare Contract Development and Manufacturing Organization Market Size, Share, Trends, Growth Outlook

Healthcare Contract Development and Manufacturing Organization Market is estimated to increase at a growth rate of 8.7% CAGR over the forecast period from 2024 to 2030.

 

The Healthcare Contract Development and Manufacturing Organization Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Contract development (Small Molecule, Large Molecule), By Contract manufacturing (Small Molecule, Large Molecule, High Potency API, Finished Dose Formulations, Medical Devices).

 

An Introduction to Healthcare Contract Development and Manufacturing Organization Market in 2024

The healthcare contract development and manufacturing organization (CDMO) market in 2024 addresses the demand for outsourcing services, contract manufacturing, and product development partnerships in the pharmaceutical, biotechnology, and medical device industries for accelerating drug discovery, formulation development, and commercialization of healthcare products, providing pharmaceutical companies, biopharmaceutical startups, and medical device manufacturers with specialized expertise, manufacturing capabilities, and regulatory support for bringing new drugs, biologics, and medical devices to market faster, safer, and more cost-effectively, leveraging the resources, infrastructure, and global networks of CDMO partners for optimizing R&D productivity, supply chain efficiency, and market competitiveness in the dynamic and highly regulated healthcare marketplace. Healthcare CDMOs offer a wide range of services and solutions, including drug substance synthesis, formulation development, analytical testing, and clinical manufacturing, as well as sterile fill-finish, packaging, and distribution services, covering the entire product lifecycle from preclinical development and early-stage research to late-stage clinical trials and commercial scale-up, enabling seamless integration, collaboration, and technology transfer between sponsors and CDMO partners for successful product development and commercialization in the pharmaceutical and medical device industries. Market dynamics are driven by factors such as the increasing complexity of pharmaceutical products and biologics, the growing trend of outsourcing R&D and manufacturing activities, and advancements in contract manufacturing technologies, quality systems, and regulatory compliance for meeting the diverse needs and requirements of healthcare companies and regulatory agencies in a competitive and dynamic healthcare market environment. Collaboration between CDMO providers, pharmaceutical sponsors, and regulatory authorities drives innovation and market expansion in healthcare CDMO services, supporting more agile, efficient, and collaborative drug development and manufacturing processes for addressing unmet medical needs, accelerating market access, and improving patient outcomes in the global healthcare marketplace.

Healthcare Contract Development and Manufacturing Organization Market Trend: Increased Outsourcing by Pharmaceutical Companies

A significant trend in the Healthcare Contract Development and Manufacturing Organization (CDMO) market is the increased outsourcing of drug development and manufacturing activities by pharmaceutical companies. As pharmaceutical companies seek to streamline operations, reduce costs, and focus on core competencies, they are increasingly turning to CDMOs for expertise in drug formulation, process development, manufacturing, and regulatory compliance. This trend reflects a strategic shift towards external partnerships to leverage the specialized capabilities and capacity of CDMOs, enabling pharmaceutical companies to accelerate drug development timelines, improve efficiency, and access advanced manufacturing technologies.

Healthcare Contract Development and Manufacturing Organization Market Driver: Growing Demand for Biologics and Complex Therapies

A key driver in the Healthcare CDMO market is the growing demand for biologics and complex therapies. With the rise of precision medicine and the development of targeted biologic drugs for various diseases, there is an increasing need for specialized manufacturing expertise and facilities capable of handling complex biopharmaceuticals, cell and gene therapies, and other advanced modalities. CDMOs play a critical role in supporting the development and manufacturing of these innovative therapies, offering specialized capabilities, infrastructure, and regulatory expertise to meet the growing demand from biopharmaceutical companies. The growing demand for biologics and complex therapies is driving the expansion of the CDMO market and fostering collaborations between pharmaceutical companies and CDMOs.

Healthcare Contract Development and Manufacturing Organization Market Opportunity: Expansion of Outsourcing Services

An opportunity for market growth in the Healthcare CDMO market lies in the expansion of outsourcing services beyond traditional drug development and manufacturing activities. CDMOs can diversify their service offerings to include a broader range of capabilities such as formulation development, analytical testing, packaging, supply chain management, and regulatory support. By providing end-to-end solutions and comprehensive support throughout the drug development lifecycle, CDMOs can offer greater value to pharmaceutical companies and differentiate themselves in the market. Furthermore, CDMOs can explore opportunities in emerging areas such as personalized medicine, orphan drugs, and biosimilars, where specialized expertise and flexible manufacturing solutions are in high demand. Expanding outsourcing services presents an opportunity for CDMOs to capture new business opportunities, strengthen client relationships, and drive revenue growth in the evolving healthcare landscape.

 

Healthcare Contract Development and Manufacturing Organization Market Segmentation

By Contract development

Small Molecule

-Preclinical

-Clinical

-Laboratory Services

Large Molecule

-Cell Line development

-Process Development

-Others

 

By Contract manufacturing

Small Molecule

Large Molecule

-MABs

-Recombinant proteins

-Others

High Potency API

Finished Dose Formulations

-Solid Dose Formulation

-Liquid Dose Formulation

-Injectable Dose Formulation

Medical Devices

-Class I

-Class II

-Class III

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Healthcare Contract Development and Manufacturing Organization Market Companies

Adare Pharma Solutions

Ajinomoto Bio-Pharma

Alcami Corp

Almac Group

Catalent Inc

IQVIA Inc

Jabil Inc

Labcorp Drug Development

Lonza

Recipharm AB

Siegfried Holding AG

Syngene International Ltd

Thermo Fisher Scientific Inc

Vetter Pharma International

*- List Not Exhaustive

 

Reasons to Buy the Healthcare Contract Development and Manufacturing Organization Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions

• Gain access to detailed insights on the Healthcare Contract Development and Manufacturing Organization Market, encompassing current market size, growth trends, and forecasts till 2030.

• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities

• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends

• Identify lucrative investment avenues and expansion opportunities within the Healthcare Contract Development and Manufacturing Organization Market industry, guided by robust, data-backed analysis.

• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics

• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain

• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics

• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

 

1 Introduction to 2024 Healthcare Contract Development and Manufacturing Organization Market

1.1 Market Overview

1.2 Quick Facts

1.3 Scope/Objective of the Study

1.4 Market Definition

1.5 Countries and Regions Analyzed

1.6 Units, Currency, and Conversions

1.7 Industry Value Chain

 

2 Research Methodology

2.1 Market Size Estimation

2.2 Sources and Research Methodology

2.3 Data Triangulation

2.4 Assumptions and Limitations

 

3 Executive Summary

3.1 Global Healthcare Contract Development and Manufacturing Organization Market Size Outlook, $ Million, 2021 to 2030

3.2 Healthcare Contract Development and Manufacturing Organization Market Outlook by Type, $ Million, 2021 to 2030

3.3 Healthcare Contract Development and Manufacturing Organization Market Outlook by Product, $ Million, 2021 to 2030

3.4 Healthcare Contract Development and Manufacturing Organization Market Outlook by Application, $ Million, 2021 to 2030

3.5 Healthcare Contract Development and Manufacturing Organization Market Outlook by Key Countries, $ Million, 2021 to 2030

 

4 Market Dynamics

4.1 Key Driving Forces of Healthcare Contract Development and Manufacturing Organization Market Industry

4.2 Key Market Trends in Healthcare Contract Development and Manufacturing Organization Market Industry

4.3 Potential Opportunities in Healthcare Contract Development and Manufacturing Organization Market Industry

4.4 Key Challenges in Healthcare Contract Development and Manufacturing Organization Market Industry

 

5 Market Factor Analysis

5.1 Competitive Landscape

5.1.1 Global Healthcare Contract Development and Manufacturing Organization Market Share by Company (%), 2023

5.1.2 Product Offerings by Company

5.2 Porter’s Five Forces Analysis

 

6 Growth Outlook Across Scenarios

6.1 Growth Analysis-Case Scenario Definitions

6.2 Low Growth Scenario Forecasts

6.3 Reference Growth Scenario Forecasts

6.4 High Growth Scenario Forecasts

 

7 Global Healthcare Contract Development and Manufacturing Organization Market Outlook By Segments

7.1 Healthcare Contract Development and Manufacturing Organization Market Outlook by Segments

By Contract development

Small Molecule

-Preclinical

-Clinical

-Laboratory Services

Large Molecule

-Cell Line development

-Process Development

-Others

By Contract manufacturing

Small Molecule

Large Molecule

-MABs

-Recombinant proteins

-Others

High Potency API

Finished Dose Formulations

-Solid Dose Formulation

-Liquid Dose Formulation

-Injectable Dose Formulation

Medical Devices

-Class I

-Class II

-Class III

 

8 North America Healthcare Contract Development and Manufacturing Organization Market Analysis And Outlook To 2030

8.1 Introduction to North America Healthcare Contract Development and Manufacturing Organization Markets in 2024

8.2 North America Healthcare Contract Development and Manufacturing Organization Market Size Outlook by Country, 2021-2030

8.2.1 United States

8.2.2 Canada

8.2.3 Mexico

8.3 North America Healthcare Contract Development and Manufacturing Organization Market size Outlook by Segments, 2021-2030

By Contract development

Small Molecule

-Preclinical

-Clinical

-Laboratory Services

Large Molecule

-Cell Line development

-Process Development

-Others

By Contract manufacturing

Small Molecule

Large Molecule

-MABs

-Recombinant proteins

-Others

High Potency API

Finished Dose Formulations

-Solid Dose Formulation

-Liquid Dose Formulation

-Injectable Dose Formulation

Medical Devices

-Class I

-Class II

-Class III

 

9 Europe Healthcare Contract Development and Manufacturing Organization Market Analysis And Outlook To 2030

9.1 Introduction to Europe Healthcare Contract Development and Manufacturing Organization Markets in 2024

9.2 Europe Healthcare Contract Development and Manufacturing Organization Market Size Outlook by Country, 2021-2030

9.2.1 Germany

9.2.2 France

9.2.3 Spain

9.2.4 United Kingdom

9.2.4 Italy

9.2.5 Russia

9.2.6 Norway

9.2.7 Rest of Europe

9.3 Europe Healthcare Contract Development and Manufacturing Organization Market Size Outlook By Segments, 2021-2030

By Contract development

Small Molecule

-Preclinical

-Clinical

-Laboratory Services

Large Molecule

-Cell Line development

-Process Development

-Others

By Contract manufacturing

Small Molecule

Large Molecule

-MABs

-Recombinant proteins

-Others

High Potency API

Finished Dose Formulations

-Solid Dose Formulation

-Liquid Dose Formulation

-Injectable Dose Formulation

Medical Devices

-Class I

-Class II

-Class III

 

10 Asia Pacific Healthcare Contract Development and Manufacturing Organization Market Analysis And Outlook To 2030

10.1 Introduction to Asia Pacific Healthcare Contract Development and Manufacturing Organization Markets in 2024

10.2 Asia Pacific Healthcare Contract Development and Manufacturing Organization Market Size Outlook by Country, 2021-2030

10.2.1 China

10.2.2 India

10.2.3 Japan

10.2.4 South Korea

10.2.5 Indonesia

10.2.6 Malaysia

10.2.7 Australia

10.2.8 Rest of Asia Pacific

10.3 Asia Pacific Healthcare Contract Development and Manufacturing Organization Market size Outlook by Segments, 2021-2030

By Contract development

Small Molecule

-Preclinical

-Clinical

-Laboratory Services

Large Molecule

-Cell Line development

-Process Development

-Others

By Contract manufacturing

Small Molecule

Large Molecule

-MABs

-Recombinant proteins

-Others

High Potency API

Finished Dose Formulations

-Solid Dose Formulation

-Liquid Dose Formulation

-Injectable Dose Formulation

Medical Devices

-Class I

-Class II

-Class III

 

11 South America Healthcare Contract Development and Manufacturing Organization Market Analysis And Outlook To 2030

11.1 Introduction to South America Healthcare Contract Development and Manufacturing Organization Markets in 2024

11.2 South America Healthcare Contract Development and Manufacturing Organization Market Size Outlook by Country, 2021-2030

11.2.1 Brazil

11.2.2 Argentina

11.2.3 Rest of South America

11.3 South America Healthcare Contract Development and Manufacturing Organization Market size Outlook by Segments, 2021-2030

By Contract development

Small Molecule

-Preclinical

-Clinical

-Laboratory Services

Large Molecule

-Cell Line development

-Process Development

-Others

By Contract manufacturing

Small Molecule

Large Molecule

-MABs

-Recombinant proteins

-Others

High Potency API

Finished Dose Formulations

-Solid Dose Formulation

-Liquid Dose Formulation

-Injectable Dose Formulation

Medical Devices

-Class I

-Class II

-Class III

 

12 Middle East And Africa Healthcare Contract Development and Manufacturing Organization Market Analysis And Outlook To 2030

12.1 Introduction to Middle East and Africa Healthcare Contract Development and Manufacturing Organization Markets in 2024

12.2 Middle East and Africa Healthcare Contract Development and Manufacturing Organization Market Size Outlook by Country, 2021-2030

12.2.1 Saudi Arabia

12.2.2 UAE

12.2.3 Oman

12.2.4 Rest of Middle East

12.2.5 Egypt

12.2.6 Nigeria

12.2.7 South Africa

12.2.8 Rest of Africa

12.3 Middle East and Africa Healthcare Contract Development and Manufacturing Organization Market size Outlook by Segments, 2021-2030

By Contract development

Small Molecule

-Preclinical

-Clinical

-Laboratory Services

Large Molecule

-Cell Line development

-Process Development

-Others

By Contract manufacturing

Small Molecule

Large Molecule

-MABs

-Recombinant proteins

-Others

High Potency API

Finished Dose Formulations

-Solid Dose Formulation

-Liquid Dose Formulation

-Injectable Dose Formulation

Medical Devices

-Class I

-Class II

-Class III

 

13 Company Profiles

13.1  Company Snapshot

13.2 SWOT Profiles

13.3 Products and Services

13.4 Recent Developments

13.5 Financial Profile

List of Companies

Adare Pharma Solutions

Ajinomoto Bio-Pharma

Alcami Corp

Almac Group

Catalent Inc

IQVIA Inc

Jabil Inc

Labcorp Drug Development

Lonza

Recipharm AB

Siegfried Holding AG

Syngene International Ltd

Thermo Fisher Scientific Inc

Vetter Pharma International

 

14 Appendix

14.1 Customization Offerings

14.2 Subscription Services

14.3 Related Reports

14.4 Publisher Expertise

Healthcare Contract Development and Manufacturing Organization Market Segmentation

By Contract development

Small Molecule

-Preclinical

-Clinical

-Laboratory Services

Large Molecule

-Cell Line development

-Process Development

-Others

 

By Contract manufacturing

Small Molecule

Large Molecule

-MABs

-Recombinant proteins

-Others

High Potency API

Finished Dose Formulations

-Solid Dose Formulation

-Liquid Dose Formulation

-Injectable Dose Formulation

Medical Devices

-Class I

-Class II

-Class III

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)